Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.6552W HIGH $110.17
Volume
447.49 K
Value Traded
86.59 M
Short % Float
15.35%
-9.03%Week
-2.48%1 Month
-13.26%3 Month
+65.29%6 Month
-60.03%5 Year
-70.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.50 B
EPS (TTM)
-2.03
P/E Ratio
-
Ent. Value
6.35 B
Total Shares
87.94 M
Float Shares
79.03 M
Insiders
10.37%
Institutions
101.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SYRE Catalyst Timeline
Dated clinical, regulatory and corporate events for Spyre Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Spyre Therapeutics, Inc.
494Total events
26Upcoming
104Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $350.0 million public offering of common stock at $85.00 per share
▲Primary Endpoint MetSPY003Clinical Data
SPY003 met primary endpoint in SKYLINE Part A with 10.0-point RHI reduction (p<0.0001) at Week 12
moderately-to-severely active ulcerative colitissource ↗
▲Secondary Endpoint DataSPY003Clinical Data
SPY003 SKYLINE Part A secondary endpoints: 20% clinical remission by modified Mayo Score and 30% endoscopic improvement
moderately-to-severely active ulcerative colitissource ↗
▲Safety Data UpdateSPY003Clinical Data
SPY003 well tolerated in SKYLINE Part A with safety profile consistent with IL-23 class
moderately-to-severely active ulcerative colitissource ↗
▲Topline ReadoutSPY003Clinical Data
SPY003 Part A 12-week induction topline data from SKYLINE
moderately-to-severely active ulcerative colitissource ↗
▼Topline ReadoutSPY072Clinical Data
Topline results from RA sub-study of SKYWAY Phase 2 trial
rheumatoid arthritissource ↗
▲Trial InitiationSPY072Trial
SKYLIGHT trial of SPY072 in combination with IL-17A/F in HS initiated
hidradenitis suppurativasource ↗
▲Enrollment CompleteSPY072Trial
SKYWAY enrollment completed with all three sub-studies over-enrolling
rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritissource ↗
●Trial InitiationSPY120Trial
SPY120 combination enrolling in Part B of SKYLINE
ulcerative colitissource ↗
●Trial InitiationSPY130Trial
SPY130 combination enrolling in Part B of SKYLINE
ulcerative colitissource ↗
●Trial InitiationSPY230Trial
SPY230 combination enrolling in Part B of SKYLINE
ulcerative colitissource ↗
▲Primary Endpoint MetSPY002Clinical Data
SPY002 met primary endpoint with 10.7-point reduction in RHI at Week 12
moderate-to-severe ulcerative colitissource ↗
◆Full ResultsSPY002Clinical Data
Part A induction results announced for SPY002
moderate-to-severe ulcerative colitissource ↗
●Enrollment UpdateSPY002Trial
Part B enrollment ongoing for SKYLINE trial
moderate-to-severe ulcerative colitissource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationSPY072Presentation
Preclinical data on TL1A inhibition in mouse models presented at EULAR 2026
rheumatic diseasessource ↗
▲Enrollment CompleteSPY072Trial
Enrollment completed for axSpA sub-study of SKYWAY basket trial
axial spondyloarthritissource ↗
▲Topline ReadoutSPY002Clinical Data
SPY002 Part A topline induction data announced
ulcerative colitissource ↗
▲Enrollment CompleteSPY072Trial
Over-enrollment completed in RA sub-study of SKYWAY trial
rheumatoid arthritissource ↗
▼Equity OfferingCorporate
Closing of underwritten public offering of 7,475,000 shares at $62.00 per share for gross proceeds of $463.5 million
▼Equity OfferingCorporate
Pricing of upsized $403.0 million public offering of common stock at $62.00 per share
▲Topline ReadoutSPY001Clinical Data
SPY001 met primary endpoint with statistically significant reduction in RHI score at Week 12
moderate-to-severe ulcerative colitissource ↗
◆Oral PresentationSPY001Presentation
Conference call to discuss SPY001 Part A induction topline results
moderate-to-severe ulcerative colitissource ↗
▲Enrollment CompleteSPY001Trial
Recruitment for SKYLINE Part A closed
moderate-to-severe ulcerative colitissource ↗
▲Trial InitiationSPY120Trial
Enrollment open for Part B combination cohorts including SPY120, SPY130, SPY230
moderate-to-severe ulcerative colitissource ↗
▲Topline ReadoutSPY001Clinical Data
SPY001 Part A topline induction data announced
ulcerative colitissource ↗
◆Topline ReadoutSPY002Clinical Data
Topline data expected for SPY002 Part A
ulcerative colitissource ↗
◆Topline ReadoutSPY003Clinical Data
SKYLINE Part A readouts expected to begin in Q2 2026
ulcerative colitissource ↗
◆Topline ReadoutSPY001Clinical Data
Part A readouts from SKYLINE platform trial expected to begin in Q2 2026
ulcerative colitissource ↗
▲Milestone PaymentPegzilarginaseApprovedCorporate
Gain of $40.0 million from milestone related to sale of pegzilarginase
▲Enrollment CompleteSPY072Trial
Recruitment for RA sub-study of SKYWAY basket trial completed
rheumatoid arthritissource ↗
◆Oral PresentationPresentation
TD Cowen 46th Annual Health Care Conference presentation and fireside chat
▲Enrollment UpdateSPY001Trial
Enrollment continuing ahead of schedule in SKYLINE Part A
ulcerative colitissource ↗
●Enrollment UpdateSPY072Trial
Enrollment on track in SKYWAY basket trial
rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritissource ↗
◆Poster PresentationSPY003Presentation
Interim Phase 1 Results for SPY003 at ECCO 2026
Inflammatory Bowel Diseasesource ↗
◆Poster PresentationSKYLINE-UCPresentation
SKYLINE-UC Platform Study Design at ECCO 2026
Ulcerative Colitissource ↗
Past FDA Catalysts and PDUFA Decisions
How SYRE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | SPY003 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$583M
Pipeline Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.1x
rNPV / MCap
Top 23%
Small Cap(rank 152 of 658)
Percentile Rank
Spyre Therapeutics, Inc. carries a moderate pipeline score (48/100), with $897M risk-adjusted pipeline value, led by SPY002-072 in Rheumatoid Arthritis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPY002-072 Small moleculeNCT07148414 | Rheumatoid Arthritis | Phase 2 | ACTIVE NOT_RECRUITING | 285 | Mar 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every SYRE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SPY003 | ulcerative colitis | Phase 2 | 2026-09-08 | primary: 10.0 points (p<0.0001); mean baseline RHI score: 17.2 ± 8.3 (SD); mean modified Mayo Score: 6.9 ± 1.2 (SD)Read More | Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD CombinationsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Burrows Scott LOfficer (Chief Financial Officer) | Option | 7,500 87,262 held | $14.50 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SYRE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SYRE for Q2 2026. | ||||
SYRE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SYRE ranks across every disease it competes in
Competitive Position is a premium feature
See how SYRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSYRE News
SYRE▼ -13.6%on this news
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Spyre Therapeutics has announced the pricing of a public offering of 4,117,648 shares at $85.00 per share, aiming to raise approximately $350 million. The proceeds will be used to advance programs in Gastroenterology, Rheumatology, and Dermatology, including late-stage development for hidradenitis suppurativa. The offering is expected to close around October 7, 2026, pending customary conditions.
Read more →SYRE▼ -13.6%on this newsshared move
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics has announced a proposed public offering of its common stock to fund its clinical programs, including late-stage development for SPY072. The offering will be managed by Jefferies, TD Cowen, Leerink Partners, and Stifel, with an option for underwriters to purchase additional shares. The company plans to use the proceeds for various research and development activities.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics has announced the approval of stock options and restricted stock units (RSUs) for two non-executive employees as part of its 2018 Equity Inducement Plan. The grants, totaling 21,424 stock options and 6,604 RSUs, are designed to enhance employee retention and align interests with the company's long-term goals. The options have a 10-year term and a competitive exercise price.
Read more →SYRESpyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Spyre Therapeutics announced positive results from Part A of the Phase 2 SKYLINE trial for SPY003, an anti-IL-23 therapy for ulcerative colitis. The trial demonstrated a statistically significant reduction in the Robart’s Histopathology Index score and established proof-of-concept for all three components of its IBD portfolio. The company plans to continue with Part B of the trial, which is currently enrolling participants.
Read more →SYRESpyre Therapeutics to Participate in Upcoming September Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences, including the Citi BioPharma Back to School Conference and the Wells Fargo Healthcare Conference. The management team will also host one-on-one meetings with investors. The company focuses on developing advanced therapies in immunology.
Read more →SYRE▼ -12.8%on this news
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Spyre Therapeutics announced topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial for SPY072. The trial showed that both doses of SPY072 provided statistically significant benefits compared to placebo on various endpoints, although the results did not meet the company's internal criteria for prioritizing its development as a monotherapy. The safety profile was consistent with expectations, supporting further exploration of TL1A antibodies in autoimmune diseases.
Read more →SYRESpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Spyre Therapeutics has launched the SPY772 program, which focuses on treating Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F. The Phase 2 SKYLIGHT trial is designed to provide clinical proof-of-concept for this innovative approach. The program aims to deliver both efficacy and convenience in treatment.
Read more →SYRESpyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported positive topline results for SPY001 and SPY002 from the Phase 2 SKYLINE trial, indicating strong efficacy and safety. The company has successfully completed enrollment for the SKYWAY trial and is on track for multiple proof-of-concept readouts in 2026. With a robust cash position of $1.1 billion, Spyre is well-positioned for future developments.
Read more →SYRESpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics announced positive results from the Part A induction of the Phase 2 SKYLINE trial for SPY002, an anti-TL1A antibody. The results indicated a statistically significant 10.7-point reduction in the RHI score, along with notable rates of clinical remission (33%) and endoscopic improvement (42%). The drug's safety profile was deemed consistent with the TL1A class, although two serious adverse events were noted. Spyre is now enrolling Part B of the trial, which will evaluate multiple combination arms.
Read more →SYRE▲ +6.3%on this newsshared move
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Spyre Therapeutics has completed enrollment for all sub-studies in the SKYWAY basket trial evaluating SPY072, an investigational therapy for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The company anticipates readouts for RA in Q3 2026 and for PsA and axSpA in Q4 2026. The swift enrollment reflects the significant unmet needs in the affected patient population and suggests potential enthusiasm for SPY072's advantages in treatment. Additionally, preclinical data supporting SPY072's efficacy in rheumatic diseases will be presented at the upcoming European Congress of Rheumatology.
Read more →SYRESpyre Therapeutics to Participate in Upcoming June Investor Conferences
Spyre Therapeutics, a biotechnology company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, announced its participation in two major investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Annual Global Healthcare Conference in Miami. Spyre's management will also hold one-on-one meetings with investors during these conferences, showcasing their commitment to investor relations and pipeline development.
Read more →SYRESpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported its first quarter 2026 financial results, highlighting positive topline data from the Phase 2 SKYLINE trial for SPY001, indicating potential best-in-class efficacy. The company has strengthened its financial position with $1.2 billion in cash and plans to accelerate readouts in its ongoing trials. The CEO expressed confidence in the pipeline's potential to redefine treatment standards for inflammatory bowel disease and rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - May 1, 2026
Spyre Therapeutics has granted stock options to four non-executive employees as part of its 2018 Equity Inducement Plan. The options, totaling 20,800 shares, were approved on May 1, 2026, and are crucial for employee retention and recruitment. The exercise price is set at $69.42, aligning with the company's closing stock price on the same day.
Read more →SYRESpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Spyre Therapeutics, Inc. has successfully closed its public offering of 7,475,000 shares, raising approximately $463.5 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The proceeds will support Spyre's development of long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Read more →About Spyre Therapeutics, Inc.
Headquarters221 CRESCENT STREET, WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next SYRE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime